Journal Mobile Options
Table of Contents
Vol. 59, No. 5, 2003
Issue release date: 2003
Horm Res 2003;59:211–221

Adulthood in Women with Turner Syndrome

Ostberg J.E. · Conway G.S.
Department of Endocrinology, Middlesex Hospital, London, UK

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Turner syndrome, resulting from a complete or partial absence of one X chromosome, is the most commonly occurring chromosomal abnormality in females. Patients have traditionally been carefully followed in paediatric practice during childhood, but were often discharged to primary care on reaching adulthood. Adults with Turner syndrome are thought to have a reduced life expectancy, mainly due to excess cardiovascular risk, but they may also have multiple comorbidities including hypothyroidism, deafness, osteoporosis and the attendant problems of oestrogen deficiency and infertility. A multidisciplinary approach to focused adult care is needed, with consideration of how to optimise surveillance strategies in these women.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Turner HH: A syndrome of infantilism, congenital webbed neck and cubitus valgus. Endocrinology 1938;23:566–574.
  2. Tesch LG, Rosenfeld RG: Morgagni, Ullrich and Turner: The discovery of gonadal dysgenesis. Endocrinologist 1995;5:327–328.
  3. Lippe B: Turner syndrome. Endocrinol Metab Clin N Am 1991;20:121–152.
  4. Price WH, Clayton JF, Collyer S, De Mey R, Wilson J: Mortality ratios, life expectancy, and causes of death in patients with Turner’s syndrome. J Epidemiol Community Health 1986;40:97–102.

    External Resources

  5. Gravholt CH, Juul S, Naeraa RW, Hansen J: Morbidity in Turner syndrome. J Clin Epidemiol 1998;51:147–158.
  6. Elsheikh M, Dunger DB, Conway GS, Wass JA: Turner’s syndrome in adulthood. Endocr Rev 2002;23:120–140.
  7. de Kerdanet M, Lucas J, Lemee F, Lecornu M: Turner’s syndrome with X-isochromosome and Hashimoto’s thyroiditis. Clin Endocrinol (Oxf) 1994;41:673–676.
  8. Elsheikh M, Wass JA, Conway GS: Autoimmune thyroid syndrome in women with Turner’s syndrome: The association with karyotype. Clin Endocrinol (Oxf) 2001;55:223–226.
  9. Barrenas ML, Nylen O, Hanson C: The influence of karyotype on the auricle, otitis media and hearing in Turner syndrome. Hear Res 1999;138:163–170.
  10. Hultcrantz M, Sylven L, Borg E: Ear and hearing problems in 44 middle-aged women with Turner’s syndrome. Hear Res 1994;76:127–132.
  11. Dennis NR, Collins AL, Crolla JA, Cockwell AE, Fisher AM, Jacobs PA: Three patients with ring (X) chromosomes and a severe phenotype. J Med Genet 1993;30:482–486.
  12. Van Dyke DL, Wiktor A, Palmer CG, Miller DA, Witt M, Babu VR, Worsham MJ, Roberson JR, Weiss L: Ullrich-Turner syndrome with a small ring X chromosome and presence of mental retardation. Am J Med Genet 1992;43:996–1005.
  13. Pasquino AM, Passeri F, Pucarelli I, Segni M, Municchi G: Spontaneous pubertal development in Turner’s syndrome. Italian Study Group for Turner’s Syndrome. J Clin Endocrinol Metab 1997;82:1810–1813.
  14. Jacobs P, Dalton P, James R, Mosse K, Power M, Robinson D, Skuse D: Turner syndrome: A cytogenetic and molecular study. Ann Hum Genet 1997;61(Pt 6):471–483.
  15. Hassold T, Benham F, Leppert M: Cytogenetic and molecular analysis of sex-chromosome monosomy. Am J Hum Genet 1988;42:534–541.
  16. Skuse DH, James RS, Bishop DV, Coppin B, Dalton P, Aamodt-Leeper G, Bacarese-Hamilton M, Creswell C, McGurk R, Jacobs PA: Evidence from Turner’s syndrome of an imprinted X-linked locus affecting cognitive function. Nature 1997;387:705–708.
  17. Chu CE, Donaldson MD, Kelnar CJ, Smail PJ, Greene SA, Paterson WF, Connor JM: Possible role of imprinting in the Turner phenotype. J Med Genet 1994;31:840–842.
  18. Carrel L, Cottle AA, Goglin KC, Willard HF: A first-generation X-inactivation profile of the human X chromosome. Proc Natl Acad Sci USA 1999;96:14440–14444.
  19. Blaschke RJ, Rappold GA: SHOX in short stature syndromes. Horm Res 2001;55(suppl 1):21–13.
  20. Davison RM, Davis CJ, Conway GS: The X chromosome and ovarian failure. Clin Endocrinol (Oxf) 1999;51:673–679.
  21. Burgoyne PS, Baker TG: Perinatal oocyte loss in XO mice and its implications for the aetiology of gonadal dysgenesis in XO women. J Reprod Fertil 1985;75:633–645.
  22. Richardson SJ, Senikas V, Nelson JF: Follicular depletion during the menopausal transition: Evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab 1987;65:1231–1237.
  23. Conway GS: The impact and management of Turner’s syndrome in adult life. Best Pract Res Clin Endocrinol Metab 2002;16:243–261.
  24. Hosoda A, Fujieda K, Matsuura N, Okuno A, Yuri K: Age-related change of pulsatile gonadotropin secretion in Turner syndrome. Pediatr Res 1991;29:196–200.
  25. Hreinsson JG, Otala M, Fridstrom M, Borgstrom B, Rasmussen C, Lundqvist M, Tuuri T, Simberg N, Mikkola M, Dunkel L, Hovatta O: Follicles are found in the ovaries of adolescent girls with Turner’s syndrome. J Clin Endocrinol Metab 2002;87:3618–3623.
  26. Tarani L, Lampariello S, Raguso G, Colloridi F, Pucarelli I, Pasquino AM, Bruni LA: Pregnancy in patients with Turner’s syndrome: Six new cases and review of literature. Gynecol Endocrinol 1998;12:83–87.
  27. Kaneko N, Kawagoe S, Hiroi M: Turner’s syndrome: Review of the literature with reference to a successful pregnancy outcome. Gynecol Obstet Invest 1990;29:81–87.
  28. Sylven L, Hagenfeldt K, Ringertz H: Bone mineral density in middle-aged women with Turner’s syndrome. Eur J Endocrinol 1995;132:47–52.
  29. Gravholt CH, Naeraa RW, Nyholm B, Gerdes LU, Christiansen E, Schmitz O, Christiansen JS: Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner’s syndrome: The impact of sex hormone replacement. Diabetes Care 1998;21:1062–1070.
  30. Chan NN, Vallance P, Colhoun HM, MacAllister RJ, Hingorani AD, Conway GS: The effects of hormone replacement therapy on endothelial function in women with Turner’s syndrome. Clin Endocrinol (Oxf) 2002;56:615–620.
  31. Elsheikh M, Bird R, Casadei B, Conway GS, Wass JA: The effect of hormone replacement therapy on cardiovascular hemodynamics in women with Turner’s syndrome. J Clin Endocrinol Metab 2000;85:614–618.
  32. Ross JL, Roeltgen D, Kushner H, Wei F, Zinn AR: The Turner syndrome-associated neurocognitive phenotype maps to distal Xp. Am J Hum Genet 2000;67:672–681.
  33. Ross JL, Stefanatos GA, Kushner H, Zinn A, Bondy C, Roeltgen D: Persistent cognitive deficits in adult women with Turner syndrome. Neurology 2002;58:218–225.
  34. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr: Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995;87:517–523.
  35. Chute CG, Willett WC, Colditz GA, Stampfer MJ, Rosner B, Speizer FE: A prospective study of reproductive history and exogenous estrogens on the risk of colorectal cancer in women. Epidemiology 1991;2:201–207.
  36. Masters KW: Treatment of Turner’s syndrome: A concern. Lancet 1996;348:681–682.
  37. Guttmann H, Weiner Z, Nikolski E, Ish-Shalom S, Itskovitz-Eldor J, Aviram M, Reisner S, Hochberg Z: Choosing an oestrogen replacement therapy in young adult women with Turner syndrome. Clin Endocrinol (Oxf) 2001;54:159–164.
  38. Khastgir G, Abdalla H, Thomas A, Korea L, Latarche L, Studd J: Oocyte donation in Turner’s syndrome: An analysis of the factors affecting the outcome. Hum Reprod 1997;12:279–285.
  39. Even L, Bronstein V, Hochberg Z: Bone maturation in girls with Turner’s syndrome. Eur J Endocrinol 1998;138:59–62.
  40. Bertelloni S, Cinquanta L, Baroncelli GI, Simi P, Rossi S, Saggese G: Volumetric bone mineral density in young women with Turner’s syndrome treated with estrogens or estrogens plus growth hormone. Horm Res 2000;53:72–76.
  41. Bechtold S, Rauch F, Noelle V, Donhauser S, Neu CM, Schoenau E, Schwarz HP: Musculoskeletal analyses of the forearm in young women with Turner syndrome: A study using peripheral quantitative computed tomography. J Clin Endocrinol Metab 2001;86:5819–5823.
  42. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, van Teunenbroek A, van Leeuwen WJ, Asarfi A, van Rijn RR, Drop SL: Bone mineral density assessed by phalangeal radiographic absorptiometry before and during long-term growth hormone treatment in girls with Turner’s syndrome participating in a randomized dose-response study. Pediatr Res 2001;50:417–422.
  43. Gravholt CH, Lauridsen AL, Brixen K, Mosekilde L, Heickendorff L, Christiansen JS: Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult turner syndrome: A cross-sectional study. J Clin Endocrinol Metab 2002;87:2798–2808.
  44. Ross JL, Long LM, Feuillan P, Cassorla F, Cutler GB Jr: Normal bone density of the wrist and spine and increased wrist fractures in girls with Turner’s syndrome. J Clin Endocrinol Metab 1991;73:355–359.
  45. Davies MC, Gulekli B, Jacobs HS: Osteoporosis in Turner’s syndrome and other forms of primary amenorrhoea. Clin Endocrinol (Oxf) 1995;43:741–746.
  46. Beckett PR, Copeland KC, Flannery TK, Sherman LD, Abrams SA: Combination growth hormone and estrogen increase bone mineralization in girls with Turner syndrome. Pediatr Res 1999;45:709–713.
  47. Mora S, Weber G, Guarneri MP, Nizzoli G, Pasolini D, Chiumello G: Effect of estrogen replacement therapy on bone mineral content in girls with Turner syndrome. Obstet Gynecol 1992;79:747–751.
  48. Saenger P, Wikland KA, Conway GS, Davenport M, Gravholt CH, Hintz R, Hovatta O, Hultcrantz M, Landin-Wilhelmsen K, Lin A, Lippe B, Pasquino AM, Ranke MB, Rosenfeld R, Silberbach M: Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab 2001;86:3061–3069.
  49. Sylven L, Hagenfeldt K, Brondum-Nielsen K, von Schoultz B: Middle-aged women with Turner’s syndrome: Medical status, hormonal treatment and social life. Acta Endocrinol (Copenh) 1991;125:359–365.
  50. Ivarsson SA, Ericsson UB, Nilsson KO, Gustafsson J, Hagenas L, Hager A, Moell C, Tuvemo T, Westphal O, Albertsson-Wikland K, et al: Thyroid autoantibodies, Turner’s syndrome and growth hormone therapy. Acta Paediatr 1995;84:63–65.
  51. Landin-Wilhelmsen K, Bryman I, Wilhelmsen L: Cardiac malformations and hypertension, but not metabolic risk factors, are common in Turner syndrome. J Clin Endocrinol Metab 2001;86:4166–4170.
  52. Cicognani A, Mazzanti L, Tassinari D, Pellacani A, Forabosco A, Landi L, Pifferi C, Cacciari E: Differences in carbohydrate tolerance in Turner syndrome depending on age and karyotype. Eur J Pediatr 1988;148:64–68.
  53. Weise M, James D, Leitner CH, Hartmann KK, Bohles HJ, Attanasio A: Glucose metabolism in Ullrich Turner syndrome: Long-term effects of therapy with human growth hormone. German Lilly UTS Study Group. Horm Res 1993;39:36–41.
  54. Caprio S, Boulware S, Diamond M, Sherwin RS, Carpenter TO, Rubin K, Amiel S, Press M, Tamborlane WV: Insulin resistance: An early metabolic defect of Turner’s syndrome. J Clin Endocrinol Metab 1991;72:832–836.
  55. Wilson DM, Frane JW, Sherman B, Johanson AJ, Hintz RL, Rosenfeld RG: Carbohydrate and lipid metabolism in Turner syndrome: Effect of therapy with growth hormone, oxandrolone, and a combination of both. J Pediatr 1988;112:210–217.
  56. Filler G, Amendt P, Kohnert KD, Devaux S, Ehrich JH: Glucose tolerance and insulin secretion in children before and during recombinant growth hormone treatment. Horm Res 1998;50:32–37.
  57. van Teunenbroek A, de Muinck Keizer-Schrama SM, Aanstoot HJ, Stijnen T, Hoogerbrugge N, Drop SL: Carbohydrate and lipid metabolism during various growth hormone dosing regimens in girls with Turner syndrome. Dutch Working Group on Growth Hormone. Metabolism 1999;48:7–14.
  58. Stoppoloni G, Prisco F, Alfano C, Iafusco D, Marrazzo G, Paolisso G: Characteristics of insulin resistance in Turner syndrome. Diabete Metab 1990;16:267–271.
  59. Holl RW, Kunze D, Etzrodt H, Teller W, Heinze E: Turner syndrome: final height, glucose tolerance, bone density and psychosocial status in 25 adult patients. Eur J Pediatr 1994;153:11–16.
  60. Ross JL, Feuillan P, Long LM, Kowal K, Kushner H, Cutler GB Jr: Lipid abnormalities in Turner syndrome. J Pediatr 1995;126:242–245.
  61. Garden AS, Diver MJ, Fraser WD: Undiagnosed morbidity in adult women with Turner’s syndrome. Clin Endocrinol (Oxf) 1996;45:589–593.
  62. Elsheikh M, Conway GS: The impact of obesity on cardiovascular risk factors in Turner’s syndrome. Clin Endocrinol (Oxf) 1998;49:447–450.
  63. Lanes R, Gunczler P, Palacios A, Villaroel O: Serum lipids, lipoprotein lp(a), and plasminogen activator inhibitor-1 in patients with Turner’s syndrome before and during growth hormone and estrogen therapy. Fertil Steril 1997;68:473–477.
  64. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–613.
  65. Sybert VP: Cardiovascular malformations and complications in Turner syndrome. Pediatrics 1998;101:E11.
  66. Mazzanti L, Cacciari E: Congenital heart disease in patients with Turner’s syndrome. Italian Study Group for Turner Syndrome (ISGTS). J Pediatr 1998;133:688–692.
  67. Gotzsche CO, Krag-Olsen B, Nielsen J, Sorensen KE, Kristensen BO: Prevalence of cardiovascular malformations and association with karyotypes in Turner’s syndrome. Arch Dis Child 1994;71:433–436.
  68. Lacro RV, Jones KL, Benirschke K: Coarctation of the aorta in Turner syndrome: A pathologic study of fetuses with nuchal cystic hygromas, hydrops fetalis, and female genitalia. Pediatrics 1988;81:445–451.
  69. Berdahl LD, Wenstrom KD, Hanson JW: Web neck anomaly and its association with congenital heart disease. Am J Med Genet 1995;56:304–307.
  70. Dawson-Falk KL, Wright AM, Bakker B, Pitlick PT, Wilson DM, Rosenfeld RG: Cardiovascular evaluation in Turner syndrome: Utility of MR imaging. Australas Radiol 1992;36:204–209.
  71. Hou JW, Hwu WL, Tsai WY, Lee JS, Wang TR, Lue HC: Cardiovascular disorders in Turner’s syndrome and its correlation to karyotype. J Formos Med Assoc 1993;92:188–189.
  72. Elsheikh M, Casadei B, Conway GS, Wass JA: Hypertension is a major risk factor for aortic root dilatation in women with Turner’s syndrome. Clin Endocrinol (Oxf) 2001;54:69–73.
  73. Allen DB, Hendricks SA, Levy JM: Aortic dilation in Turner syndrome. J Pediatr 1986;109:302–305.
  74. Lin AE, Lippe B, Rosenfeld RG: Further delineation of aortic dilation, dissection, and rupture in patients with Turner syndrome. Pediatrics 1998;102:e12
  75. Nagel TC, Tesch LG: ART and high risk patients! Fertil Steril 1997;68:748–749.
  76. Garvey P, Elovitz M, Landsberger EJ: Aortic dissection and myocardial infarction in a pregnant patient with Turner syndrome. Obstet Gynecol 1998;91:864.
  77. Ostberg JE, Conway GS: Accelerated Aortic Root Dilatation in Turner Syndrome. Endocrine Abstracts, vol 3. 21st Joint Meeting of the British Endocrine Societies, 2002.
  78. Henry WL, Ware J, Gardin JM, Hepner SI, McKay J, Weiner M: Echocardiographic measurements in normal subjects: Growth-related changes that occur between infancy and early adulthood. Circulation 1978;57:278–285.
  79. Lin AE, Lippe BM, Geffner ME, Gomes A, Lois JF, Barton CW, Rosenthal A, Friedman WF: Aortic dilation, dissection, and rupture in patients with Turner syndrome. J Pediatr 1986;109:820–826.
  80. Rosenfeld RG, Tesch LG, Rodriguez-Rigau LJ, et al: Recommendations for diagnosis, treatment, and management of individuals with Turner syndrome (abstract). Endocrinologist 1994;4:351–358.
  81. Nathwani NC, Unwin R, Brook CG, Hindmarsh PC: Blood pressure and Turner syndrome. Clin Endocrinol (Oxf) 2000;52:363–370.
  82. Virdis R, Cantu MC, Ghizzoni L, Ammenti A, Nori G, Volta C, Cravidi C, Vanelli M, Balestrazzi P, Bernasconi S, et al: Blood pressure behaviour and control in Turner syndrome. Clin Exp Hypertens A 1986;8:787–791.
  83. Price DA, Clayton PE, Crowne EH, Roberts CR: Safety and efficacy of human growth hormone treatment in girls with Turner syndrome. Horm Res 1993;39(suppl 2):44–48.
  84. van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD: Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996;347:714–718.
  85. Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
  86. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49–57.
  87. Conway GS, Davies M, Merry A: Treatment of Turner’s syndrome. Lancet 1996;348:1590–1591.
  88. Lippe B, Geffner ME, Dietrich RB, Boechat MI, Kangarloo H: Renal malformations in patients with Turner syndrome: Imaging in 141 patients. Pediatrics 1988;82:852–856.
  89. Flynn MT, Ekstrom L, De Arce M, Costigan C, Hoey HM: Prevalence of renal malformation in Turner syndrome. Pediatr Nephrol 1996;10:498–500.
  90. Hellstrom P, Ottelin J, Siniluoto T, Paivansalo M, Kyllonen AP: Renal cell carcinoma in horseshoe kidney associated with Turner syndrome and caval extension. Urology 1989;34:46–48.
  91. Knudtzon J, Svane S: Turner’s syndrome associated with chronic inflammatory bowel disease: A case report and review of the literature. Acta Med Scand 1988;223:375–378.
  92. Hayward PA, Satsangi J, Jewell DP: Inflammatory bowel disease and the X chromosome. QJM 1996;89:713–718.
  93. Bonamico M, Bottaro G, Pasquino AM, Caruso-Nicoletti M, Mariani P, Gemme G, Paradiso E, Ragusa MC, Spina M: Celiac disease and Turner syndrome. J Pediatr Gastroenterol Nutr 1998;26:496–499.
  94. O’Hare JP, Hamilton M, Davies JD, Corrall RJ, Mountford R: Oestrogen deficiency and bleeding from large bowel telangiectasia in Turner’s syndrome. J R Soc Med 1986;79:746–747.
  95. Elsheikh M, Hodgson HJ, Wass JA, Conway GS: Hormone replacement therapy may improve hepatic function in women with Turner’s syndrome. Clin Endocrinol (Oxf) 2001;55:227–231.
  96. Albareda MM, Gallego A, Enriquez J, Rodriguez JL, Webb SM: Biochemical liver abnormalities in Turner’s syndrome. Eur J Gastroenterol Hepatol 1999;11:1037–1039.
  97. Garavelli L, Donadio A, Banchini G, Fornaciari G, Plancher AC, Franchi F, Gardini G: Liver abnormalities and portal hypertension in Ullrich-Turner syndrome. Am J Med Genet 1998;80:180–182.
  98. Wemme H, Pohlenz J, Schonberger W: Effect of oestrogen/gestagen replacement therapy on liver enzymes in patients with Ullrich-Turner syndrome. Eur J Pediatr 1995;154:807–810.
  99. Jospe N, Orlowski CC, Furlanetto RW: Comparison of transdermal and oral estrogen therapy in girls with Turner’s syndrome. J Pediatr Endocrinol Metab 1995;8:111–116.
  100. Barrenas M, Landin-Wilhelmsen K, Hanson C: Ear and hearing in relation to genotype and growth in Turner syndrome. Hear Res 2000;144:21–28.
  101. Stenberg AE, Nylen O, Windh M, Hultcrantz M: Otological problems in children with Turner’s syndrome. Hear Res 1998;124:85–90.
  102. Stenberg AE, Wang H, Fish J 3rd, Schrott-Fischer A, Sahlin L, Hultcrantz M: Estrogen receptors in the normal adult and developing human inner ear and in Turner’s syndrome. Hear Res 2001;157:87–92.
  103. Sybert VP: The adult patient with Turner syndrome; in Albertsson-Wikland, K, Ranke M (eds): Turner Syndrome in a Life-Span Perspective: Research and clinical aspects. Excerpta Medica. Int Congr Series, vol 1089, pp 1–330, 1995.
  104. Chrousos GA, Ross JL, Chrousos G, Chu FC, Kenigsberg D, Cutler G Jr, Loriaux DL: Ocular findings in Turner syndrome: A prospective study. Ophthalmology 1984;91:926–928.
  105. Adhikary HP: Ocular manifestations of Turner’s syndrome. Trans Ophthalmol Soc UK 1981;101:395–396.
  106. Downey J, Elkin EJ, Ehrhardt AA, Meyer-Bahlburg HF, Bell JJ, Morishima A: Cognitive ability and everyday functioning in women with Turner syndrome. J Learn Disabil 1991;24:32–39.
  107. Romans SM, Stefanatos G, Roeltgen DP, Kushner H, Ross JL: Transition to young adulthood in Ullrich-Turner syndrome: Neurodevelopmental changes. Am J Med Genet 1998;79:140–147.
  108. McCauley E, Kay T, Ito J, Treder R: The Turner syndrome: Cognitive deficits, affective discrimination, and behavior problems. Child Dev 1987;58:464–473.
  109. Murphy DG, Mentis MJ, Pietrini P, Grady C, Daly E, Haxby JV, De La Granja M, Allen G, Largay K, White BJ, Powell CM, Horwitz B, Rapoport SI, Schapiro MB: A PET study of Turner’s syndrome: Effects of sex steroids and the X chromosome on brain. Biol Psychiatry 1997;41:285–298.
  110. Murphy DG, Allen G, Haxby JV, Largay KA, Daly E, White BJ, Powell CM, Schapiro MB: The effects of sex steroids, and the X chromosome, on female brain function: A study of the neuropsychology of adult Turner syndrome. Neuropsychologia 1994;32:1309–1323.
  111. Ross JL, Roeltgen D, Feuillan P, Kushner H, Cutler GB Jr: Effects of estrogen on nonverbal processing speed and motor function in girls with Turner’s syndrome. J Clin Endocrinol Metab 1998;83:3198–3204.
  112. Ross JL, Feuillan P, Kushner H, Roeltgen D, Cutler GB Jr: Absence of growth hormone effects on cognitive function in girls with Turner syndrome. J Clin Endocrinol Metab 1997;82:1814–1817.
  113. Delooz J, Van den Berghe H, Swillen A, Kleczkowska A, Fryns JP: Turner syndrome patients as adults: A study of their cognitive profile, psychosocial functioning and psychopathological findings. Genet Couns 1993;4:169–179.
  114. Ross JL, McCauley E, Roeltgen D, Long L, Kushner H, Feuillan P, Cutler GB Jr: Self-concept and behavior in adolescent girls with Turner syndrome: Potential estrogen effects. J Clin Endocrinol Metab 1996;81:926–931.
  115. Toublanc JE, Thibaud F, Lecointre C: Psychosocial and sexual outcome in women with Turner syndrome. Contracept Fertil Sex 1997;25:633–638.
  116. Manuel M, Katayama PK, Jones HW Jr: The age of occurrence of gonadal tumors in intersex patients with a Y chromosome. Am J Obstet Gynecol 1976;124:293–300.
  117. Savage MO, Lowe DG: Gonadal neoplasia and abnormal sexual differentiation. Clin Endocrinol (Oxf) 1990;32:519–533.
  118. Quilter CR, Taylor K, Conway GS, Nathwani N, Delhanty JD: Cytogenetic and molecular investigations of Y chromosome sequences and their role in Turner syndrome. Ann Hum Genet 1998;62:99–106.
  119. McCarty KS Jr, Barton TK, Peete CH Jr, Creasman WT: Gonadal dysgenesis with adenocarcinoma of the endometrium: An electron microscopic and steroid receptor analyses with a review of the literature. Cancer 1978;42:512–520.
  120. Hasle H, Olsen JH, Nielsen J, Hansen J, Friedrich U, Tommerup N: Occurrence of cancer in women with Turner syndrome. Br J Cancer 1996;73:1156–1159.
  121. Hebert-Croteau N: A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev 1998;7:653–659.
  122. Swerdlow AJ, Higgins CD, Adlard P, Preece MA: Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: A cohort study. Lancet 2002;360:273–277.
  123. Raiti S, Moore WV, Van Vliet G, Kaplan SL: Growth-stimulating effects of human growth hormone therapy in patients with Turner syndrome. J Pediatr 1986;109:944–949.
  124. Tanner JM, Whitehouse RH, Hughes PC, Vince FP: Effect of human growth hormone treatment for 1 to 7 years on growth of 100 children, with growth hormone deficiency, low birthweight, inherited smallness, Turner’s syndrome, and other complaints. Arch Dis Child 1971;46:745–782.

    External Resources

  125. Zvulunov A, Wyatt DT, Laud PW, Esterly NB: Influence of genetic and environmental factors on melanocytic naevi: A lesson from Turner’s syndrome. Br J Dermatol 1998;138:993–997.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50